Rezafungin

07/01/2011 - "Substantially increased liver pathology in mice having the B6 and A/J Idd10 haplotypes correlates with reduced expression of CD101 on dendritic cells, macrophages, and granulocytes following infection, delayed clearance of N. "
09/11/2021 - "Collectively, these studies showed that rezafungin could both prevent infection and eliminate P. "
01/01/2022 - "Overall, these data suggest an important role for CD101-expressing CD4 T cells at all stages of HIV/SIV infection and a potential rationale for targeting CD101 to limit HIV pathogenesis and persistence, particularly at mucosal sites."
01/01/2022 - "Phenotypic analyses and single-cell RNAseq profiling revealed that CD101 marked CD4 Tregs with high immunosuppressive potential, distinct from CD101- Tregs, and these cells also were ideal target cells for HIV/SIV infection, with higher expression of CCR5 and α4β7 in the gut mucosa. "
11/01/2021 - "We report on the successful ongoing compassionate use of rezafungin obtained through expanded access for over 1 year in a patient with a multidrug-resistant Candida glabrata mediastinal infection from a vascular graft infection and retained foreign material."

01/01/2021 - "Similarly, in the aspergillosis model, survival rates increased with drug concentrations and when rezafungin was administered closer to the time of fungal challenge. "
11/01/2016 - "CD101 showed antifungal activity against Candida and Aspergillus infections in neutropenic mice. "
12/01/2019 - "Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy."
01/01/2021 - "Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia."
01/01/2021 - "Rezafungin was evaluated in in vivo studies of prophylactic efficacy using immunosuppressed mouse models of invasive candidiasis, aspergillosis, and Pneumocystis pneumonia. "

01/01/2018 - "The present study examined the pharmacodynamic activity of CD101 using the neutropenic invasive candidiasis mouse model against select Candida albicans (n = 4), C. "
06/01/2023 - "This article summarizes the milestones in the development of rezafungin leading to the first approval for the treatment of candidaemia and invasive candidiasis."
06/01/2023 - "In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options. "
01/01/2021 - "Rezafungin: a novel antifungal for the treatment of invasive candidiasis."
11/01/2019 - "We evaluated the pharmacodynamics (PD) of rezafungin against 4 Candida tropicalis and 4 Candida dubliniensis strains, using the neutropenic mouse invasive candidiasis model. "

07/01/2023 - "The following topics regarding candidemia only and ICIs were reviewed and addressed: i) pathogenesis; ii) epidemiology and temporal evolution of Candida species; iii) clinical approach; iv) potential role of the novel long-acting rezafungin in the treatment of ICIs. "
11/28/2023 - "Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis."
10/18/2021 - "The objective of this analysis was to develop a population pharmacokinetic (PK) model to characterize the disposition of rezafungin in plasma following intravenous (IV) administration in healthy volunteers and in patients with candidemia and/or invasive candidiasis. "
01/01/2018 - "These analyses support the use of single and once-weekly rezafungin regimens for the treatment of patients with candidemia and/or candidiasis due to C. "
01/01/2018 - "CD101 is currently being evaluated as a once-weekly intravenous (i.v.) infusion for the treatment of candidemia and invasive candidiasis. "

06/01/2023 - "Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis."
11/23/2023 - "New antifungals development: rezafungin in candidiasis treatment."
07/01/2023 - "Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin."
06/01/2023 - "Cost analyses of drugs against candidiasis, such as rezafungin, are thus of great interest to healthcare payers. "
01/01/2023 - "Rezafungin and invasive candida infections: a new game changing antifungal?"